Oslo 16.09.2013 - The CEO of Bionor Pharma, Anker Lundemose is interviewed in this article about the AIDS conference in Kuala Lumpur July 2013. Dr. Lundemose emphasizes the Danish HIV research aiming at emptying the HIV reservoirs in the body, which potentially can contribute to a Functional Cure for HIV
HivNorge is a Norwegian organization based in Oslo, for people living with HIV. Their main objectives are to take care of rights and interests of HIV-positive people in the society, to work for a better understanding of their situation, and to combat fear, prejudice and discrimination. Their magazine Positive has in this article focused on the AIDS Conference in Kuala Lumpur July 2013, and the new recommendations from WHO (World Health Organization).
Anker Lundemose was present at the “Towards an HIV cure”, an academic symposium connected to the AIDS conference, where also the novel science conducted by the Danish HIV researchers was presented. Bionor Pharma is encouraged by the ongoing discussions with these scientist, where the plan is to combine their reservoir-research using HDAC inhibitors (“kick”), with Bionor Pharma`s HIV vaccine candidate Vacc-4x (“kill”). The aim of this “kick and kill” combination treatment is to help keep the HIV viral load under control in the absence of HIV medication.
View the whole article here
- See more at: http://www.bionorpharma.com/en/News/2013/Media_Coverage/Bionor+Pharma+Featured+in+Positiv+Magazine%2C+From+the+AIDS+Conference+in+Kuala+Lumpur.b7C_wlvM2v.ips#sthash.ZjIDgQyU.dpuf